GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Shares Outstanding (EOP)

Gala Pharmaceutical (Gala Pharmaceutical) Shares Outstanding (EOP) : 107.67 Mil (As of May. 2019)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Gala Pharmaceutical's shares outstanding for the quarter that ended in May. 2019 was 107.67 Mil.

Gala Pharmaceutical's quarterly shares outstanding increased from Feb. 2019 (95.20 Mil) to May. 2019 (107.67 Mil). It means Gala Pharmaceutical issued new shares from Feb. 2019 to May. 2019 .

Gala Pharmaceutical's annual shares outstanding increased from Nov. 2017 (35.70 Mil) to Nov. 2018 (92.01 Mil). It means Gala Pharmaceutical issued new shares from Nov. 2017 to Nov. 2018 .


Gala Pharmaceutical Shares Outstanding (EOP) Historical Data

The historical data trend for Gala Pharmaceutical's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical Shares Outstanding (EOP) Chart

Gala Pharmaceutical Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18
Shares Outstanding (EOP)
Get a 7-Day Free Trial 1.19 1.30 1.37 35.70 92.01

Gala Pharmaceutical Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.55 58.70 92.01 95.20 107.67

Competitive Comparison of Gala Pharmaceutical's Shares Outstanding (EOP)

For the Biotechnology subindustry, Gala Pharmaceutical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gala Pharmaceutical's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gala Pharmaceutical's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Gala Pharmaceutical's Shares Outstanding (EOP) falls into.



Gala Pharmaceutical Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Gala Pharmaceutical  (OTCPK:GLPH) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Gala Pharmaceutical Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.